PHARMING GROUP NV (PHARM.AS)

NL0010391025 - Common Stock

0.7965  -0.01 (-1.42%)

Fundamental Rating

3

Taking everything into account, PHARM scores 3 out of 10 in our fundamental rating. PHARM was compared to 75 industry peers in the Biotechnology industry. The financial health of PHARM is average, but there are quite some concerns on its profitability. PHARM is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

PHARM had negative earnings in the past year.
PHARM had a negative operating cash flow in the past year.
Of the past 5 years PHARM 4 years were profitable.
PHARM had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -2.88%, PHARM is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
PHARM has a Return On Equity of -6.09%. This is in the better half of the industry: PHARM outperforms 72.86% of its industry peers.
Industry RankSector Rank
ROA -2.88%
ROE -6.09%
ROIC N/A
ROA(3y)1.65%
ROA(5y)5.8%
ROE(3y)3.38%
ROE(5y)12.69%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PHARM has a better Gross Margin (88.55%) than 87.14% of its industry peers.
In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
PHARM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y1.43%

More info and screens

4

2. Health

2.1 Basic Checks

PHARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHARM has more shares outstanding
PHARM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHARM has been reduced compared to a year ago.

2.2 Solvency

PHARM has an Altman-Z score of 0.44. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.44, PHARM perfoms like the industry average, outperforming 51.43% of the companies in the same industry.
A Debt/Equity ratio of 0.76 indicates that PHARM is somewhat dependend on debt financing.
The Debt to Equity ratio of PHARM (0.76) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF N/A
Altman-Z 0.44
ROIC/WACCN/A
WACC4.95%

2.3 Liquidity

PHARM has a Current Ratio of 4.06. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.06, PHARM is in the better half of the industry, outperforming 74.29% of the companies in the same industry.
A Quick Ratio of 3.33 indicates that PHARM has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.33, PHARM is doing good in the industry, outperforming 68.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.06
Quick Ratio 3.33

More info and screens

5

3. Growth

3.1 Past

PHARM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.13%.
PHARM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.30%.
PHARM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.35% yearly.
EPS 1Y (TTM)-3.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
Revenue 1Y (TTM)19.3%
Revenue growth 3Y4.96%
Revenue growth 5Y11.35%
Sales Q2Q%12.28%

3.2 Future

PHARM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.41% yearly.
The Revenue is expected to grow by 11.77% on average over the next years. This is quite good.
EPS Next Y61.38%
EPS Next 2Y76.82%
EPS Next 3Y79.32%
EPS Next 5Y58.41%
Revenue Next Year20.59%
Revenue Next 2Y14.82%
Revenue Next 3Y14.32%
Revenue Next 5Y11.77%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

PHARM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
PHARM is valuated quite expensively with a Price/Forward Earnings ratio of 47.61.
Based on the Price/Forward Earnings ratio, PHARM is valued a bit cheaper than the industry average as 77.14% of the companies are valued more expensively.
PHARM's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.55.
Industry RankSector Rank
PE N/A
Fwd PE 47.61

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PHARM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHARM's earnings are expected to grow with 79.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y76.82%
EPS Next 3Y79.32%

More info and screens

0

5. Dividend

5.1 Amount

PHARM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMING GROUP NV

AMS:PHARM (10/30/2024, 7:00:00 PM)

0.7965

-0.01 (-1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap54.03M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 47.61
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.88%
ROE -6.09%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 88.55%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.76
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.06
Quick Ratio 3.33
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-3.13%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y61.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.3%
Revenue growth 3Y4.96%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y